Affiliation: Indiana University
- Use of botulinum toxin type A in poststroke spasticityAllison Brashear
Indiana University School of Medicine, 550 University Blvd, Rm 6620, Indianapolis, IN 46202, USA
Expert Rev Neurother 3:271-7. 2003..Side effects of the injections were mild and self-limited. Botulinum toxin type A injections for upper extremity spasticity are safe and efficacious, and should be considered as first choice in the treatment of this disorder...
- Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trialAllison Brashear
Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Arch Phys Med Rehabil 85:705-9. 2004..To determine whether botulinum toxin type B (BTX-B) is effective in controlling upper-limb spasticity...
- Treatment with botulinum toxin type B for upper-limb spasticityAllison Brashear
Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202 5250, USA
Arch Phys Med Rehabil 84:103-7. 2003..To determine if botulinum toxin type B (MyoBloc) decreases spasticity...
- Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticityAllison Brashear
Indiana University School of Medicine, Indianapolis, IN, USA
Arch Phys Med Rehabil 83:1349-54. 2002..To evaluate the reliability of the Ashworth Scale and the Disability Assessment Scale (DAS) in poststroke patients with upper-limb spasticity and functional disability...
- Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a strokeAllison Brashear
Department of Neurology, Indiana University School of Medicine, Indianapolis 46202, USA
N Engl J Med 347:395-400. 2002..Spasticity is a disabling complication of stroke, and it is uncertain whether intramuscular injections of botulinum toxin type A reduce disability in persons with spasticity of the wrist and fingers after a stroke...
- Botulinum toxin type B: a new injectable treatment for cervical dystoniaA Brashear
Indiana University School of Medicine, Department of Neurology, 550 University Boulevard, Room 6620, Indianapolis, IN 46202 5250, USA
Expert Opin Investig Drugs 10:2191-9. 2001..Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD...
- The safety and tolerability of botulinum toxins for the treatment of cervical dystoniaAllison Brashear
Indiana University Medical Center, Department of Neurology, CL 291, Indianapolis, IN 46202 5250, USA
Expert Opin Drug Saf 4:241-9. 2005....
- The botulinum toxins in the treatment of cervical dystoniaA Brashear
Department of Neurology, Indiana University Medical Center, Indianapolis 46202-5250, USA
Semin Neurol 21:85-90. 2001..The potential availability of both forms of toxin will allow physicians to offer further treatment options to patients with CD...
- Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyD M Simpson
Department of Neurology, Mount Sinai Medical Center, New York, NY, USA
Neurology 70:1699-706. 2008..To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of movement disorders...
- Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystoniaJ Jankovic
Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
Neurology 67:2233-5. 2006..One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy...
- Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13P L Kramer
Department of Neurology, Oregon Health Sciences University, Portland 97201, USA
Ann Neurol 46:176-82. 1999..Identification of the genetic defect in RDP holds promise for understanding the underlying disease processes of both of these more common diseases...
- Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystoniaAllison Brashear
Department of Neurology, Indiana University Medical Center, 550 University Boulevard, Room 6620, Indianapolis, IN 46202, USA
Adv Ther 22:49-55. 2005..48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation...
- Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trialsStuart A Yablon
Brain Injury Program, Methodist Rehabilitation Center, Jackson, Mississippi 39216, USA
Clin Ther 29:683-90. 2007..The purpose of this study was to investigate the incidence of neutralizing antibody (NAb) formation in patients with poststroke spasticity treated with a specific formulation of botulinum toxin type A (BoNTA)...
- Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patientsElie P Elovic
Kessler Medical Rehabilitation Research and Education Center, West Orange, NJ, USA
Arch Phys Med Rehabil 89:799-806. 2008....
- Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a strokeMartin K Childers
Dept of Physical Medicine and Rehabilitation, University of Missouri at Columbia, One Hospital Drive, DCO 46 00, Columbia, MO 65212, USA
Arch Phys Med Rehabil 85:1063-9. 2004..To test the hypothesis that intramuscular (IM) botulinum toxin type A (BTX) reduces excessive muscle tone in a dose-dependent manner in the elbow, wrist, and fingers of patients who experience spasticity after a stroke...
- Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assayMitchell F Brin
Allergan, Inc, Global Drug Development, Irvine, California, USA
Mov Disord 23:1353-60. 2008..The current formulation of BoNTA rarely causes neutralizing antibody formation in CD subjects treated < or =4 years...
- Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesiaKarmen K Yoder
Department of Radiology, Division of Research, Section of Imaging Science, 950 W Walnut St, Research Institute 2, Room E124, Indianapolis, IN 46202, USA
Schizophr Res 71:371-5. 2004..Significant and trend-level inverse correlations were found between DAT BP in the striatum, and especially the severity of negative symptom scores, but also cognitive, and depression/anxiety scores on the PANSS...